Tempus AI Stock Price – Current Close Performance Forecast
Tempus AI, Inc. trades on the NASDAQ under the ticker TEM. The stock closed at $42.94 on April 10, 2026, marking a 2.76% decline from the prior session’s close of $44.16. Trading activity that day spanned a low of $42.41 to a high of $45.95, with approximately 6.84 million shares changing hands. The company, a healthcare technology firm leveraging artificial intelligence and machine learning to generate data-driven clinical insights, has drawn significant attention from both retail and institutional investors since its public debut.
For investors tracking TEM, real-time pricing data is available through official investor relations channels and major market data platforms. Given the stock’s notable volatility and sensitivity to earnings announcements, understanding the full picture—beyond today’s closing price—requires examining recent performance trends, analyst outlooks, and the broader context of the company’s financial health.
This article provides a comprehensive overview of Tempus AI’s current stock position, historical performance, analyst sentiment, and the key factors investors should monitor as the company navigates a competitive landscape in AI-powered healthcare.
What is the Current Tempus AI (TEM) Stock Price?
Tempus AI, Inc. (NASDAQ: TEM) closed at $42.94 on April 10, 2026, according to the company’s official investor relations page. The stock slipped 2.76% from the previous close of $44.16. Intraday trading ranged between $42.41 and $45.95, with volume reaching approximately 6.84 million shares.
Prices reported across different platforms showed minor variations due to timing differences. Robinhood displayed $43.21, Kraken reported $43.30, and after-hours activity on StockTwits indicated $43.37. These discrepancies reflect normal intraday fluctuations rather than fundamental price divergence.
The official investor relations site confirms the $42.94 closing price for April 10, 2026. For real-time quotes, investors can consult the Nasdaq market activity page or the company’s own stock quote and chart tool. Markets were closed on April 11–12, 2026 due to the weekend.
Tempus AI Stock Overview
Key Insights on Tempus AI Stock
- The stock is currently trading well below its 52-week high of $104.32, representing a significant pullback from the October 2025 peak.
- Despite recent declines, TEM has delivered approximately 98% gains over the past year, underscoring strong long-term momentum.
- The company remains unprofitable, posting a net loss of approximately $705.81 million against full-year revenue of $693.40 million.
- Revenue growth is robust at 83% year-over-year, though the company fell short of its full-year profitability target.
- The stock carries a high beta of approximately 3.04, indicating volatility roughly three times that of the broader market.
- Average daily trading volume ranges between 4.69 million and 4.76 million shares, suggesting strong liquidity.
- Institutional interest is evident, with notable investors including Cathie Wood’s Ark Invest and figures associated with Nancy Pelosi trades.
Tempus AI Stock Snapshot
| Metric | Value |
|---|---|
| P/E Ratio (TTM) | -30.52 |
| EPS (TTM/Annual) | -$1.18 to -$1.41 |
| Market Cap | $7.68B (~$7.77B on some platforms) |
| 52-Week High | $104.32 |
| 52-Week Low | $38.79 |
| Avg. Daily Volume | 4.69M–4.76M shares |
| Beta (1Y) | 3.04 |
| Shares Outstanding | ~179.40M (Float 96.24M) |
| Dividend Yield | None reported |
| 52-Week Performance | +98.24% |
| All-Time High Date | October 9, 2025 |
| All-Time Low Date | June 25, 2024 |
Market capitalization figures vary across sources—$7.68B on some platforms versus $15.04B on others. This discrepancy likely stems from differences in share class calculations or timing of outstanding share counts. The $7.68B figure aligns with data from Nasdaq and Robinhood and is treated as the primary reference here.
How Has Tempus AI Stock Performed Recently?
Tempus AI’s recent performance tells a story of high volatility tempered by substantial long-term gains. The stock achieved its all-time high of $104.32 on October 9, 2025, only to pull back sharply in subsequent months. The 52-week low of $38.79 was recorded on June 25, 2024, shortly after the IPO, and the stock has since oscillated dramatically between those extremes.
On a shorter timeframe, TEM posted monthly gains of 10.98% but shed 3.06% in the most recent weekly period. The weekly volatility measure sits at 6.31%, consistent with the elevated beta reading. Shares have consolidated above the $70 support level, with technical analysts watching for a potential breakout above the $76.80–$77 resistance zone.
Performance Drivers and Recent Catalysts
Several high-profile events have shaped recent trading activity. Ark Invest, led by Cathie Wood, purchased approximately $11 million worth of TEM shares during a dip, signaling confidence in the company’s AI-healthcare thesis. Separately, trades associated with Nancy Pelosi have been cited by some analysts as coinciding with a 100% surge in the stock price.
Ahead of the Q4 earnings release, the stock climbed 6.85%, reflecting pre-announcement optimism. The Q4 report itself showed a net loss but exceeded revenue estimates, reinforcing the company’s top-line trajectory even as profitability remains elusive.
What is the Tempus AI Stock Forecast and Analyst Ratings?
Analyst sentiment on TEM spans a wide range. Price targets vary from a minimum of $60 to a maximum of $110 per share, indicating significant disagreement about the stock’s near-term trajectory. The divergence reflects uncertainty around when—or whether—Tempus AI will achieve sustainable profitability.
Bullish observers point to the company’s 83% revenue growth as evidence of strong market adoption for its AI-driven diagnostics and data platforms. The consolidation phase following the October 2025 highs is viewed by some analysts as healthy, suggesting the stock is building a base for the next leg up.
Earnings Outlook and Upcoming Catalysts
The next major earnings report is scheduled for November 4, covering Q3 2025 results. Analysts project an EPS of -$0.19 and revenue of approximately $328.86 million. The company’s track record of beating revenue estimates while missing profitability targets suggests investors should focus on top-line momentum when evaluating upcoming reports.
The full-year picture shows revenue of $693.40 million against a net loss of $705.81 million. Tempus AI previously set a profitability target that it did not meet, a factor that could weigh on sentiment if not addressed in upcoming guidance.
Institutional Activity and Sentiment Signals
Institutional investors have shown heightened interest in TEM during price corrections. Ark Invest’s $11 million dip purchase stands out as a notable signal given the fund’s focus on disruptive technology companies. High-profile political trading activity has also drawn attention, though the causal relationship between those trades and price movements remains debated among market participants.
Tempus AI’s negative P/E ratio of -30.52 and ongoing net losses indicate the stock is not yet profitable. The elevated beta of 3.04 means TEM moves more sharply than the broader market in both directions. Investors considering positions should weigh the company’s revenue growth against its persistent losses and the inherent volatility of AI-sector stocks.
When Did Tempus AI Go Public and Key IPO Details?
Tempus AI completed its public listing on the NASDAQ, trading under the Class A Common Stock ticker TEM. Based on the 52-week low date of June 25, 2024, the IPO occurred sometime in mid-2024. The stock’s subsequent performance—ranging from a low of $22.89 in late June 2024 to a peak of $104.32 in October 2025—reflects the heightened volatility typical of recently listed technology companies in high-growth sectors.
The company operates as a healthcare technology firm that applies artificial intelligence and machine learning to clinical data. Tempus AI’s platform is designed to help healthcare providers and researchers derive actionable insights from large-scale biological and medical data sets.
IPO Market Context
Tempus AI entered the public markets during a period of significant investor appetite for AI-related offerings. The post-IPO price action—characterized by rapid swings between $22.89 and $104.32—underscores both the enthusiasm surrounding AI healthcare applications and the uncertainty about when these companies can convert revenue growth into consistent profitability.
Tempus AI Stock Timeline
The following timeline outlines key events in Tempus AI’s public history since its IPO in mid-2024.
- June 25, 2024 — Stock records all-time low of $22.89, marking the bottom of early post-IPO trading.
- Mid-2024 — Tempus AI completes NASDAQ listing under ticker TEM (Class A Common Stock).
- Q4 2024 — Company reports net loss but beats revenue estimates; stock gains 6.85% pre-earnings.
- 2024–2025 — 83% year-over-year revenue growth reported; profitability target missed for the full year.
- October 9, 2025 — Stock reaches all-time high of $104.32.
- Late 2025 — Ark Invest, led by Cathie Wood, purchases approximately $11 million of TEM on a dip.
- 2025–2026 — Stock enters consolidation phase above $70 support; weekly volatility at 6.31%.
- November 4, 2025 — Scheduled Q3 2025 earnings release (EPS est. -$0.19; revenue est. $328.86M).
- April 10, 2026 — Stock closes at $42.94, down 2.76% on daily volume of 6.84 million shares.
Stock Price Certainty: What We Know and What Remains Unclear
When evaluating a volatile growth stock like Tempus AI, distinguishing between established facts and ongoing uncertainties is essential for informed decision-making.
| Established Information | Uncertainties and Risks |
|---|---|
| Stock closed at $42.94 on April 10, 2026 (official IR data). | Whether the stock will sustain above $70 support or break through $76.80–$77 resistance. |
| Full-year revenue of $693.40M; net loss of $705.81M. | Timeline for achieving consistent profitability remains undefined. |
| 52-week range: $104.32 (high) / $38.79 (low). | How regulatory developments in AI healthcare will affect the company’s operating environment. |
| Analyst price targets range from $60 to $110. | The impact of institutional trading activity (Ark, Pelosi trades) on sustained price direction. |
| Revenue growth rate of 83% year-over-year. | Market cap discrepancy across sources ($7.68B vs. $15.04B) requires clarification. |
| Q4 2024 results showed loss but beat revenue estimates. | Whether the November Q3 2025 earnings will meet, beat, or miss consensus estimates. |
Analysis: Tempus AI in the AI Healthcare Landscape
Tempus AI operates at the intersection of two high-demand sectors: healthcare and artificial intelligence. The company’s platform processes large volumes of clinical and molecular data, offering insights intended to support precision medicine and research initiatives. This positioning aligns with broader industry trends toward data-driven healthcare delivery.
The 83% revenue growth rate demonstrates substantial market traction, but the persistent gap between revenue and profitability raises questions about the company’s unit economics and path to sustainable earnings. Many AI healthcare peers face similar challenges, suggesting the sector as a whole is prioritizing expansion over near-term margins.
Investors evaluating TEM alongside broader AI healthcare investments should consider factors such as regulatory approvals for AI-assisted diagnostic tools, data privacy frameworks, and competition from both established healthcare technology firms and emerging AI-native companies. For additional context on housing and economic indicators that may influence market conditions, review our Windsor Homes for Sale – MLS Prices, Neighborhoods & 2026 Outlook guide.
Expert Quotes and Sources
The following sources inform this analysis. Where available, direct quotations or attributed statements from these sources are included.
“Tempus AI, Inc. is a healthcare technology company applying artificial intelligence and machine learning to healthcare, focusing on data-driven insights.”
— Finviz company profile
“Bullish sentiment: Strong run-up, healthy consolidation; Cathie Wood/Ark bought $11M dip.”
— Finviz market commentary
All price and financial data in this article draws from official investor relations disclosures, Nasdaq market data, and third-party platforms as cited throughout. Investors are encouraged to consult primary sources—including the Tempus AI investor relations site and Nasdaq’s TEM stock page—for the most current information.
What’s Next for Tempus AI Stock
Investors with TEM on their watchlist should monitor the November 4 earnings release as the next major catalyst. The combination of high volatility, significant institutional holdings, and an ambitious growth strategy means the stock is likely to remain sensitive to both quarterly results and broader AI sector sentiment.
Until Tempus AI demonstrates a credible path to profitability, the stock will continue to trade largely on revenue trajectory and market perception of its competitive position in AI healthcare. For additional context on market conditions that may influence investor behavior, see our Windsor Homes for Sale – 2025 Prices and Buyer Guide.
Frequently Asked Questions
What is Tempus AI’s current stock price?
Tempus AI (NASDAQ: TEM) closed at $42.94 on April 10, 2026, according to official investor relations data.
When does Tempus AI report earnings next?
Tempus AI is scheduled to report Q3 2025 earnings on November 4, with an estimated EPS of -$0.19 and revenue of approximately $328.86 million.
Is Tempus AI profitable?
No. Tempus AI posted a full-year net loss of approximately $705.81 million against revenue of $693.40 million. The company is growing rapidly but remains unprofitable.
What is the Tempus AI stock forecast?
Analyst price targets for TEM range from $60 (minimum) to $110 (maximum). The stock has demonstrated significant volatility, with a 52-week range of $38.79 to $104.32.
What does Tempus AI do?
Tempus AI is a healthcare technology company that applies artificial intelligence and machine learning to clinical and biological data, aiming to generate data-driven insights for healthcare providers and researchers.
When did Tempus AI IPO?
Tempus AI listed on the NASDAQ in mid-2024. The all-time low of $22.89 was recorded on June 25, 2024, and the all-time high of $104.32 followed on October 9, 2025.
Does Tempus AI pay a dividend?
No dividend yield has been reported for Tempus AI. As an unprofitable growth company, Tempus AI reinvests earnings into expansion rather than distributing them to shareholders.
How volatile is Tempus AI stock?
Very volatile. TEM carries a 1-year beta of approximately 3.04, meaning it tends to move roughly three times the magnitude of the broader market. Weekly volatility sits at 6.31%.
Where can I buy Tempus AI stock?
Tempus AI trades on the NASDAQ under the ticker TEM and can be purchased through any licensed brokerage platform that offers access to U.S. equity markets.
Who are the major institutional investors in Tempus AI?
Notable institutional investors include Cathie Wood’s Ark Invest, which purchased approximately $11 million of TEM during a price dip. Trading activity linked to high-profile political investors has also been reported.
More related posts
Ravens vs Bills Match Player Stats: 41-40 Thriller
Rise of the Guardians: Sequel Cancelled, Flop Status, Netflix?
Hotels in London Ontario: Neighborhoods, Safety & Top Picks
Translate English to Vietnamese: Free Tools Guide
Ten Foot Henry Calgary Menu: Prices, Hours & Parking
Punta Cana Trip Deals – Best All-Inclusive Packages 2025
Anker Power Bank Recall – What Owners Need to Know
Games Like Wasteland 3 – Top Turn-Based RPG Alternatives
